The Pandemic Pipeline

Can we be more prepared than this?
The Pandemic Pipeline

Share this post

Choose a social network to share with, or copy the shortened URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks
Credit: Plrang GFX / Alamy Stock Photo

In the midst of the COVID-19 pandemic, eyes have turned expectantly to the biopharmaceutical industry. But responding in real time is not what our drug development infrastructure has been designed to do. A lengthy clinical testing and regulatory review process can take years to navigate. Furthermore, the tendency of governments to cease funding against new viruses or bioterrorism agents once the threat subsides (as with the 2002 SARS epidemic) has kept many therapies from reaching the end zone. Understanding this, groups around the globe have been working to speed pandemic response times and shave inefficiencies from vaccine development; their efforts will now be put to the test by COVID-19. 

Nature Biotechnology took a deep dive into lessons learned from previous pandemics and gauged current efforts against this international crisis. You can find the feature here.  

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in